Radiopharmaceutical company Telix Pharmaceuticals Ltd. is continuing its buying spree to shore up dominance in the radiopharmaceutical market with its latest acquisition of RLS Radiopharmacies for $250 million to expand its U.S. manufacturing presence and establish a next-generation radiometal production network. Read More
Ascletis Pharma Inc. is entering the obesity space, announcing it has begun two phase I trials for ASC-30, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist that can be dosed once monthly subcutaneously and once daily orally for treating obesity. Read More
Both the biotech industry and Hong Kong have become strategic points for China as the People’s Republic of China works to lay a biotech “belt and road” through Asia to expand global influence. Read More
Although details are scant, Shanghai Fosun Pharmaceutical Co. Ltd. plans to buy out partner Kite Pharma Inc. (now Gilead Sciences Inc.) in the Fosun Pharma Kite Biotechnology Co. Ltd. joint venture for $27 million. Read More
Innovent Biologics Inc. unveiled for the first time safety and efficacy data of IBI-354, an HER2 monoclonal antibody-camptothecin derivative conjugate that shows promising efficacy signals across a range of advanced solid tumors, during the European Society of Medical Oncology (ESMO) 2024 Congress. An HER2-targeted antibody-drug conjugate developed using Innovent's topoisomerase inhibitor NT3 platform, IBI-354 combines a hydrophilic linker design with a hydrophobic payload to enhance the bystander effect, targeting adjacent antigen-low or negative tumor cells. Read More
The U.S. Court of Appeals for the Federal Circuit reined in a district court that invalidated three claims in an Astellas Pharma Inc. patent protecting bladder drug Myrbetriq (mirabegron) based on a issue that was never argued. Read More
An innovation that has kickstarted a revolution in the study and practice of health care is getting even more attention. Three scientists who pioneered the discovery and development of glucagon-like peptide-1 (GLP-1)-based obesity treatments have been named 2024 Lasker Award winners. Read More
By treating mice with antifibrotic drugs, researchers were able to stave off functional decline of the ovaries. Six weeks of systemic treatment with the antifibrotic pirfenidone, which is approved for the treatment of idiopathic pulmonary fibrosis, in early middle age improved both the morphology and the endocrine function of the animals’ ovaries at 1 year of age. Read More
Australia is the skin cancer capital of the world, but with a shortage of dermatologists, patients often wait too long to get skin checks that could end up costing them their lives. Read More
Chengdian (Suzhou) Biopharmaceutical Co. Ltd. has received IND clearance from the FDA, allowing it to initiate a first-in-human phase I trial of CD-001. Read More
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Asieris, Biosyngen, Dizal, Eisai, Gan & Lee, Immvira, Immutep, Innovent, Insilico. Read More
Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: Acadia Pharmaceuticals , Axcelead Drug Discovery Partners. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Amplia, GSK, Nicox, Samsung Bioepis, Simcere. Read More
